回盛生物(300871.SZ):擬建設1000噸/年泰樂菌素項目的生產線
格隆匯 9 月 10日丨回盛生物(300871.SZ)公佈,為完善公司產品結構、豐富產品鏈、製劑/原料一體化,減少市場原料藥價格波動對產品影響,減少市場原料藥產量波動對公司產品的影響,擬建設1000噸/年泰樂菌素項目的生產線,主要建設內容為發酵車間、提取車間、精製車間、動力、配電、菌種室、儲罐區、倉庫及配套環保設施等。
項目總投資3.8億元,其中建設工程投資8220.64萬元,設備投資(含運雜安裝費)25181萬元,其他費用4598.36萬元。
截止2020年8月31日,該項目投入及未來計劃投入情況,如下:

擬在漢口銀行股份有限公司武昌支行開設超募資金專項賬户,進行專户管理。擬超募資金投入金額少於項目投資總額,不足部分由公司以自有資金或通過其他融資方式解決。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.